Objective To study the diagnosis and trea tm ent of urolithiasis in patients after renal transplantation. Methods 5 cases of urinary tract stone in patients after renal transplantat ion were diagnosed and treated.In 1 case,the stone was a remnant of the stone in the donor kidney,in 3 cases,the stone was secondary to a sternotic ureterocysto stomy stoma,in the other case,a stent in the urinary tract was complicated by st one formation.Surgical removal of the stone with ureter-bladder reanastomosis w as carried out for 3,in one of which ESWL has failed.Conventional nonsurgical meas ures was adopted for 2. Results The patients have been f ollowed up for 1～13 years with all the patients and the transplants surviving.I n one of the patients with nonsurgical management,the transplanted kidney has al ready survived for 13 years. Conclusions The treatment o f urinary tract stone in a transplanted kidney is similar to the conventional pr inciples,relieving the block and removal of the stone.Risk factors of uric acid stone formation should be taken care of.

OBJECTIVETo investigate miR-20a expression in human glioma and normal brain tissues and its effect on the proliferation of glioma cells in vitro.

METHODSThe expression of miR-20a was detected in human normal brain tissues and glioma tissues by real-time RT-PCR. miR-20a mimics were synthesized and transfected into U251 cells via liposome, and the cell proliferation were detected using MTT assay and flow cytometry.

RESULTSThe glioma tissues showed significantly up-regulated expression of miR-20a compared with normal brain tissues (P=0.035). The expression level of miR-20a was higher in high-grade than in low-grade gliomas. miR-20a mimics significantly enhanced the proliferation of U251 cells and the percentage of S-phase cells.

CONCLUSIONmiR-20a shows potent effect in promoting the growth of glioma cells, suggesting its important role in the pathogenesis of human glioma.

Adult ; Brain Neoplasms ; genetics ; metabolism ; pathology ; Cell Line, Tumor ; Cell Proliferation ; Female ; Glioma ; genetics ; metabolism ; pathology ; Humans ; Male ; MicroRNAs ; genetics ; metabolism ; Middle Aged ; Real-Time Polymerase Chain Reaction ; Young Adult

Objective To investigate clinicopathologic characteristics,individualized immunotherapy and prognosis of antibody-mediated rejection (AMR)after renal transplantation.Methods Clinical data of 32 patients,who were confirmed as AMR after renal transplantation by pathology and admitted in the Department of Urology and Renal Transplantation of the First Affiliated Hospital of Henan Traditional Medical College from January 2010 to December 2013,were retrospectively studied.The corresponding immunological intervention was adopted according to the clinicopathologic characteristics of different patients.The indicators including renal function,panel reactive antibody (PRA)and serum immunoglobulin (Ig)G,IgA and IgM level before and after treatment were determined,and adverse reactions were observed.Results Of all 32 patients, 18 developed acute antibody-mediated rejection (AAMR ) and 14 developed chronic antibody-mediated rejection (CAMR).Of 13 PRA-positive patients,8 (62%,8 /13)cases were with donor specific antibody and 5 (38%,5 /13)cases were with non-donor specific antibody.The primary pathological manifestations of early AAMR were changes of acute tubular necrosis (ATN ),peritubular capillary inflammation,glomerulitis, fibrinoid necrosis of small arteries,linear C4d deposition in peritubular capillaries (PTC)and immunoglobulin or C3 deposition in arterial wall.The pathological manifestations of CAMR were changes of glomerulopathy, splitting of PTC basement membrane,fibrous intimal thickening and diffuse C4d deposition in PTC.After treatment,the renal function of 20 (63%,20 /32)patients returned to normal,the renal function of 7 (22%, 7 /32)patients were stable,the serum creatinine (Scr)of 5 (16%,5 /32)patients increased slowly.Of such 5 patients,2 (2 /5 )patients continued hemodialysis,3 (3 /5 )patients did not need hemodialysis and no patient died.The indicators including blood urea nitrogen (BUN),Scr,PRA and serum IgG,IgA and IgM after treatment decreased significantly when compared with those before treatment (all in P <0.01).No serious adverse reaction was noted during the treatment.Conclusions AMR may manifest as AAMR or CAMR after renal transplantation.The gold standard for diagnosing AMR is pathologic biopsy of transplant kidney.To adopt effective individualized immunotherapy in time is the critical measure for treatment of AMR.